Top Buy Stocks
Sign In
NASDAQ:ABUS
Arbutus Biopharma Corporation Stock News
$3.12
-0.0400 (-1.27%)
At Close: May 15, 2025
Arbutus Biopharma (ABUS) Reports Q1 Loss, Tops Revenue Estimates
09:45am, Wednesday, 14'th May 2025
Arbutus Biopharma (ABUS) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of a loss of $0.09. This compares to loss of $0.10 per share a year ago.
Arbutus Reports First Quarter 2025 Financial Results and Provides Corporate Update
07:30am, Wednesday, 14'th May 2025
Imdusiran combination therapy has functionally cured 8 patients with chronic hepatitis B (cHBV) to date, including 2 patients who received no interferon
Data highlighted in late-breaker poster presentation shows that imdusiran achieves functional cure in chronic hepatitis B (cHBV) patients when combined with VTP-300 and low dose nivolumab In a Phase 1
Will Arbutus Biopharma (ABUS) Report Negative Q1 Earnings? What You Should Know
11:05am, Thursday, 24'th Apr 2025
Arbutus (ABUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Arbutus to Present Imdusiran and AB-101 Data at EASL Congress 2025
02:01am, Wednesday, 23'rd Apr 2025
Five abstracts accepted for poster presentations WARMINSTER, Pa., April 23, 2025 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage
All You Need to Know About Arbutus (ABUS) Rating Upgrade to Buy
01:00pm, Monday, 31'st Mar 2025
Arbutus (ABUS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Is Arbutus Biopharma (ABUS) Outperforming Other Medical Stocks This Year?
10:42am, Monday, 31'st Mar 2025
Here is how Arbutus Biopharma (ABUS) and Aveanna Healthcare (AVAH) have performed compared to their sector so far this year.
Arbutus Biopharma (ABUS) Reports Q4 Loss, Tops Revenue Estimates
09:45am, Thursday, 27'th Mar 2025
Arbutus Biopharma (ABUS) came out with a quarterly loss of $0.07 per share versus the Zacks Consensus Estimate of a loss of $0.08. This compares to loss of $0.12 per share a year ago.
Arbutus Reports Fourth Quarter and Year End 2024 Financial Results and Provides Corporate Update
07:30am, Thursday, 27'th Mar 2025
Claim construction hearing for Pfizer/BioNTech mRNA-LNP vaccine litigation occurred in December 2024; outcome pending
CHICAGO--(BUSINESS WIRE)--GE HealthCare (Nasdaq: GEHC) announced the launch of Invenia™ Automated Breast Ultrasound (ABUS) Premium, the latest 3D ultrasound offering advanced artificial intelligence
Genevant Sciences and Arbutus Biopharma Initiate International Patent Infringement Enforcement Actions Against Moderna
09:15am, Monday, 03'rd Mar 2025
BASEL, Switzerland and VANCOUVER, B.C. and WARMINSTER, Pa., March 03, 2025 (GLOBE NEWSWIRE) -- Genevant Sciences, a leading nucleic acid delivery company with world-class platforms and a robust lipid
Arbutus Announces Changes to Board of Directors and Appointment of Lindsay Androski as CEO
07:00am, Tuesday, 25'th Feb 2025
WARMINSTER, Pa., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company focused on infectious
Arbutus, Burford Capital, And Cadiz With Chris DeMuth Jr.
03:40pm, Thursday, 30'th Jan 2025
Chris DeMuth, Jr. shares some of his current top picks. Arbutus Biopharma is a promising investment due to its potential litigation value from IP claims against Pfizer and Moderna related to COVID-19
Arbutus Provides 2025 Corporate and Financial Update
07:30am, Monday, 13'th Jan 2025
Initiating Phase 2b clinical trial in first half of 2025 after achieving a meaningful functional cure rate in cHBV patients treated with imdusiran and interferon
Arbutus: Positive Imdusiran Data Leads To Phase 2B Development
07:56am, Tuesday, 07'th Jan 2025
Company's phase 2a trial of Imdusiran with pegylated interferon alfa-2a achieved a functional cure in 25% of Hepatitis B patients. The company is developing its own in-house oral PD-L1 inhibitor, AB-1
